Claims for Patent: 10,487,107

Summary for Patent: 10,487,107

Title:	Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
Abstract:	The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.
Inventor(s):	Morein; Bror (Uppsala, SE), Berenjian; Saideh (Uppsala, SE), Hu; Kafei (Uppsala, SE)
Assignee:	MX ADJUVAC AB (SE)
Application Number:	15/815,488
Patent Claims:	1. A stable two component nanoparticle comprising a first component comprising cholesterol and a second component from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin in a ratio of first component to second component from 1:10 to 10:1, wherein said nanoparticle has a particle diameter in the range of 12-35 nanometers and wherein said nanoparticle does not comprise a phospholipid. 2. The stable two component nanoparticle of claim 1, wherein said nanoparticles are formed from a sterol membrane and a quillaja saponin micelle in an aqueous solution. 3. The stable two component nanoparticle of claim 1, wherein the quillaja saponin is quillaja saponinn fraction QHC from Quillaja saponaria Molina. 4. The stable two component nanoparticle of claim 1, further comprising at least one of an amphipathic or a hydrophobic molecule. 5. The stable two component nanoparticle of claim 4, wherein the amphipathic or hydrophobic molecule is at least one member selected from an antigen, an adjuvant, a targeting molecule, a pharmaceutical compound and a food related compound. 6. The stable two component nanoparticle of claim 4, wherein the amphipathic or hydrophobic molecule is chosen from Diterpenoid (DT), VLX40, Busulfan, roscovitine and vitamin D3. 7. A composition comprising one or more of the nanoparticles according to claim 1. 8. The composition according to claim 7, wherein different quillaja saponin fractions are each incorporated in different nanoparticles. 9. The composition according to claim 7, further comprising pharmaceutically acceptable buffers, diluents excipients, adjuvants and/or carriers. 10. The composition according to claim 7 further comprising a vaccine. 11. The composition according to claim 10, wherein the vaccine is a pandemic flu vaccine. 12. The composition according to claim 10, wherein the vaccine is a seasonal influenza virus vaccine. 13. The composition according to claim 10, wherein the vaccine is a pandemic influenza virus vaccine. 14. The composition according to claim 10, wherein the vaccine is a vaccine against a biological weapon. 15. The composition according to claim 7, further comprising at least one of an anticancer drug, a platinum coordination compound, a taxane compound, a camptohtecin compounds, an anti-tumor vinca alkaloid, an anti-tumor nucleoside derivative, a nitrogen mustard or nitrosourea alkylating agent, an anti-tumor anthracycline derivative, a trastzumab, an anti-tumor podophyllotoxin derivative, an antimetabolite, a steroid, an inhibitor of a mammalian target of rapamycin (mTOR), an agent for treating cancer, Cytarabin, Daunorubicin, Paclitaxel, Docetaxel, Cabazitaxel, Toricsel, and Trabectidin. 16. A method for treatment of cancer, comprising administering to a patient in need thereof a pharmaceutically effective amount of the two component nanoparticles according to claim 1.

Details for Patent 10,487,107

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Seqirus Vaccines Limited	FLUVIRIN	influenza virus vaccine	Injection	103837	November 03, 1998	10,487,107	2037-11-16
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	December 09, 1999	10,487,107	2037-11-16
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	December 23, 2009	10,487,107	2037-11-16
Sanofi Pasteur Inc.	FLUZONE, FLUZONE HD QUADRIVALENT, FLUZONE HIGH DOSE, FLUZONE INTRADERMAL, FLUZONE QUADRIVALENT	influenza virus vaccine	Injection	103914	May 09, 2011	10,487,107	2037-11-16